Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04850040 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma Resectable

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Start date: May 6, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, single-center, clinical research.This trial will explore the efficacy and safety of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.

NCT ID: NCT04843943 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Start date: May 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).

NCT ID: NCT04834986 Not yet recruiting - Clinical trials for Resectable Hepatocellular Carcinoma

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Start date: April 30, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.

NCT ID: NCT04825470 Not yet recruiting - Liver Cancer Clinical Trials

Liver Transplantation for Unresectable GIST Liver Metastases

TRANSGIST
Start date: May 2022
Phase: N/A
Study type: Interventional

Liver Transplantation for Unresectable GIST Liver Metastases

NCT ID: NCT04730388 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

HEPATOFIT
Start date: January 18, 2021
Phase:
Study type: Observational

Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère

NCT ID: NCT04665609 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Start date: March 5, 2021
Phase: Phase 3
Study type: Interventional

In this study, investigators aimed to evaluated the efficacy and safety of microwave ablation combined with anlotinib and TQB2450 Solution in patients with advanced hepatocellular carcinoma. Patients were randomly assigned at a one-to-one ratio to receive microwave ablation plus anlotinib and TQB2450 Solution or microwave ablation plus TQB2450 Solution. Primary end points were objective response rate(ORR). Second end points include overall survival, progression-free survival and disease control rate. Safety was assessed in all patients.

NCT ID: NCT04665362 Not yet recruiting - Clinical trials for Advanced/Metastatic Hepatocellular Carcinoma

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Start date: January 25, 2021
Phase: Phase 1
Study type: Interventional

This is a single arm and open-label phase I trial to evaluate the safety, tolerability and efficacy of the oncolytic virus M1 (M1-c6v1)(iv 1×109 CCIC50, 1 dose per day, on day 1-5 each 28 day cycle) combined with anti-PD-1 antibody SHR-1201 (iv, 200 mg, once every two weeks) and Apatinib (po. 250 mg qd ) in the patients with advanced/metastatic hepatocellular carcinoma. 10 participants will be sequentially enrolled. The treatment duration is 12 months. All patients continue combination treatment until disease progression, unacceptable toxicity, death, or discontinuation for any reason.

NCT ID: NCT04640116 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Transjugular intrahepatic portosystemic shunt (TIPS) could effectively decrease portal hypertension-related complications. This study intends to evaluate the efficacy and safety of TIPS combined with subsequent microwave ablation in HCC patients with refractory ascites.

NCT ID: NCT04627363 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm clinical study to preliminarily observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line therapy for advanced HCC.

NCT ID: NCT04597970 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC

OXRI
Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

Purpose:explore the effectiveness and safety of transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)